Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Paclitaxel 7Cisplatin 6Radiation 4Carboplatin 4tislelizumab 3Surgical Procedures, Operative 3Radiotherapy 3Immune Checkpoint Inhibitors 3Capecitabine 3camrelizumab 2Platinum Compounds 2Endoscopic Mucosal Resection 2Drug Therapy 2Albumin-Bound Paclitaxel 2nedaplatin 1lobaplatin 1Tranexamic Acid 1Thalidomide 1TP protocol 1Stents 1Standard of Care 1Oxaliplatin 1Nutrition Assessment 1Neoadjuvant Therapy 1Muscle Stretching Exercises 1Indocyanine Green 1Heart Rate 1Fluorouracil 1Exercise 1Epinephrine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Esophageal Neoplasms × Thalidomide × Clear all
NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Henan Cancer Hospital

Phase 2 Unknown
132 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡